tbd

Saudat Fadeyi is a science-driven executive leader with over 17 years of experience in the pharmaceutical and biotechnology industry. She brings deep expertise across global drug development, corporate strategy, business development, and licensing, with a focus on advancing transformative therapies from discovery through commercialization.

As Head of Business Development & Strategy at Samyang Biopharm USA, Saudat leads strategic initiatives to advance a pipeline of novel non-viral gene delivery platforms into the clinic through external innovation, partnerships, and licensing. She is focused on building high-value collaborations that accelerate next-generation genetic medicines.

Previously, she led Business Development at Ovid Therapeutics, where she executed impactful transactions across multiple stages of development for rare neurological diseases. Saudat began her career at Schering-Plough and has held progressive leadership roles at multiple companies including Pfizer and Sage Therapeutics. She has driven programs across diverse therapeutic areas including oncology, metabolic disorders, infectious disease, inflammation, and neurology and played a critical role in advancing early- and late-stage assets, including several marketed products. Leveraging a background in translational research and clinical development, she bridges science, strategy, and value creation in dealmaking. Saudat holds a PhD in Cancer Biology, an MBA in Pharmaceutical Management, and completed postdoctoral training at the National Institutes of Health (NIH), NCI Cancer Vaccine Branch, specializing in immuno-oncology and vaccine development.

Samuel Zhang, PhD, is responsible for global strategy and business development at Innovent. Dr. Zhang has a PhD in Molecular Biology from Columbia University, an MBA from the Wharton School of the University of Pennsylvania, and a BS in Biology from Peking University.

Dr Zhang brings over 20 years of industry experience across the entire pharmaceutical research, development and commercialization spectrum. He has a successful track record in identifying emerging industry trends and promising assets at an early stage, enabling major R&D decisions, and facilitating strategic transactions. Prior to joining Innovent, Dr Zhang served as CBO at Gracell and NeoImmuneTech and led their global partnership discussions, including the $1.2B Gracell acquisition by AstraZeneca. He has also held positions of increasing responsibility at Eli Lilly, Pfizer, Bristol-Myers Squibb, Novartis, and Merus.

Dr. Chan Hee Chon is the Chief Technology Officer (CTO) of Inventage Lab, a South Korea–based company specializing in microfluidics-driven pharmaceutical manufacturing platforms. With over 20 years of research experience, Dr. Chon is a recognized expert in the application of microfluidics technology to drug delivery systems.

At Inventage Lab, Dr. Chon has led the innovation of proprietary manufacturing platforms, integrating microfluidic technologies into manufacturing systems and processes for drug delivery. His contributions have resulted in the development and commercialization of two breakthrough platforms: DrugFluidic, a manufacturing technology for long-acting injectables and GeneFluidic, a manufacturing platform for producing gene delivery nanoparticles used in gene therapy and vaccines.

His work continues to push the boundaries of next-generation drug delivery, bridging cutting-edge engineering with pharmaceutical science.

Tamás Kiss, Ph.D. is a pharmaceutical scientist and formulation project manager with a strong background in pharmaceutical technology and international project coordination. He holds a Ph.D. from the University of Szeged, where he specialized in the development of advanced drug delivery systems using a Quality by Design (QbD) framework.

Currently, Tamás works at CarboHyde, a cyclodextrin-focused R&D company, where he manages multiple client-driven formulation projects in parallel. His responsibilities include end-to-end project coordination, client communication, and ensuring compliance with international standards such as ICH guidelines and pharmacopeias. In addition to his formulation role, he leads cosmetic business development at CarboHyde, establishing a new strategic direction for the company.

Tamás is highly client-oriented and committed to delivering scientifically grounded, regulatory-aligned solutions tailored to complex therapeutic needs. His work spans cyclodextrin-enabled delivery systems for both small molecules and biologics, including applications in gene delivery.

With experience in both academia and industry, Tamás combines scientific rigor, organizational efficiency, and strong communication skills to drive innovation across disciplines. He is passionate about creating meaningful health impact through translational science and collaborative development.

Beth McBride DiLauri is Director of Portfolio Marketing for BD Medical, Pharmaceutical Systems. Her responsibilities include developing portfolio strategies and leading commercialization of drug delivery solutions for biologics. She is passionate about developing insights and solutions to help pharmaceutical company partners achieve their combination product commercialization goals while enabling patient care.

Beth has dedicated her tenure at BD to developing and executing portfolio strategies based on deep market and customer insights across drug-device combination products, medical devices, diagnostics and healthcare IT. Beth spent the early part of her career focused on structuring strategic partnerships, venture investments and acquisitions within BD and at Transcend Therapeutics. Beth received a Masters in Business Administration from the Tuck School of Business at Dartmouth College and a Bachelors degree from Boston College.